
Pharma/Biotech CFO Industry Insights
4 Minute Read
Why CFOs are shifting from Reactive Net Revenue Management to Proactive Net Revenue Optimization? By Jen Sharpe, VP, Advisory Services at IntegriChain.

4 Minute Read
Why CFOs are shifting from Reactive Net Revenue Management to Proactive Net Revenue Optimization? By Jen Sharpe, VP, Advisory Services at IntegriChain.

2 Minute Read
Efficient inventory management is crucial for healthcare organizations to ensure patient satisfaction, maintain financial stability, and mitigate supply chain risks. Moving forward, drug manufacturers must adapt their inventory management...

3 Minute Read
The gross-to-net process, essential for understanding net revenue, demands a keen awareness of every piece of data and business drivers upstream. In this blog, we'll explore the critical considerations...

6 Minute Read
For the majority of life science and biotech companies, January is a time of closing the books, wrapping up year end results, and preparing for the annual audit. This...

4 Minute Read
In the pharmaceutical and biotech sector, "gross-to-net" (GTN) now goes beyond managing manufacturer discounts. It covers revenue management, reporting, and analytics. The Revenue Analytics Collaborative (RAC) started surveying members...

2 Minute Read
This is the second installment of our two-part blog post covering our webinar series discussing the advantages that channel analytics and downstream inventory analytics have when it comes to...

4 Minute Read
This is the first installment of our two-part blog post covering our webinar series discussing the advantages that channel analytics and downstream inventory analytics have when it comes to...

2 Minute Read
Manufacturers considering taking a WAC price increase this year should be aware of the impact on their GTN line items.

2 Minute Read
In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...